Thomas Godec

Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial

Hywel C Williams, Fenella Wojnarowska, Gudula Kirtschig et al. · The Lancet · 2017 · 212 citations · Full text

Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial

Ajay Gupta, Judith Mackay, Andrew Whitehouse et al. · The Lancet · 2018 · 116 citations · Full text

Hypertension, Legacy Study, Health Policy +12

Changes in HbA1c and weight, and treatment persistence, over the 18 months following initiation of second-line therapy in patients with type 2 diabetes: results from the United Kingdom Clinical Practice Research Datalink

John Wilding, Thomas Godec, Kamlesh Khunti et al. · BMC Medicine · 2018 · 48 citations · Full text

Patterns of glycaemic control in patients with type 2 diabetes mellitus initiating second‐line therapy after metformin monotherapy: <scp>R</scp> etrospective data for 10 256 individuals from the <scp>U</scp> nited <scp>K</scp> ingdom and <scp>G</scp> ermany

Kamlesh Khunti, Thomas Godec, Jesús Medina et al. · Diabetes Obesity and Metabolism · 2017 · 47 citations · Full text

Legacy benefits of blood pressure treatment on cardiovascular events are primarily mediated by improved blood pressure variability: the ASCOT trial

Ajay Gupta, William Whiteley, Thomas Godec et al. · European Heart Journal · 2024 · 44 citations · Full text